A groundbreaking discovery has shed light on the stubborn nature of certain lung cancers, offering hope for a new treatment approach. Lung cancer, a global killer, has found an unexpected ally in a key gene mutation.
Scientists from ASTAR Institute of Molecular and Cell Biology (ASTAR IMCB) have unraveled a mysterious survival mechanism employed by lung cancer cells with EGFR mutations. These mutations, found in a significant portion of adenocarcinoma cases in Southeast Asia, initially respond to targeted drugs but eventually develop resistance.
The puzzle has been why the faulty proteins produced by mutant EGFR are so resilient. While normal proteins are recycled, these mutants persist, leading to uncontrollable cell growth. But here's where it gets controversial: scientists have discovered a protective mechanism that keeps these mutant proteins active and driving cancer growth.
Through an extensive genome-wide screen, researchers identified a process where cancer cells flood their environment with ATP, a molecule usually used for energy. This excess ATP activates a receptor called P2Y2, which, with the help of integrin β1, forms a protective barrier around the mutant EGFR. This barrier prevents the faulty protein from being broken down, allowing it to continue its cancerous activity.
The team's findings were confirmed in human cancer tissue samples, where elevated levels of P2Y2 and integrin β1 were observed in tumors compared to healthy tissue. Dr. Gandhi Boopathy, a Senior Scientist at A*STAR IMCB, described this as cancer cells deploying "molecular bodyguards" to shield the mutant protein.
The good news is that P2Y2, being on the cell surface, is more accessible to drugs than targets deeper within the cell. By targeting this system, researchers can potentially disrupt the stability of the mutant EGFR, offering a new strategy to tackle drug resistance.
The team's research, led by Professor Wanjin Hong, a President's Science Award recipient, has also explored the potential of a natural compound, kaempferol, found in vegetables like kale and broccoli. In laboratory models, daily treatment with kaempferol significantly reduced drug-resistant human lung tumors over 24 days, targeting only cancer cells with EGFR mutations.
Professor Hong emphasized that by targeting the P2Y2 system, they're not just attacking the mutation but the very structure that keeps it stable. This approach could be a game-changer, potentially working alongside existing drugs to overcome or prevent resistance.
The study, a collaborative effort involving researchers from A*STAR, the National University of Singapore, and other international partners, offers a new direction in the fight against drug-resistant lung cancer. It raises the question: Could this discovery lead to a paradigm shift in cancer treatment, offering hope to those battling this deadly disease?
